Executives
-
Altshuler DavidEVP, Chief Scientific Officer -
Kewalramani ReshmaCEO & President
-
Biller JonathanEVP and Chief Legal Officer
-
Leiden Jeffrey MExecutive Chairman
-
Bozic CarmenEVP and CMO
-
Atkinson Edward Morrow IiiEVP, Chief Technical Ops. Off.
-
Sachdev AmitEVP Chief Patient & Ext Af Off
-
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
-
Ambrose KristenSVP & Chief Accounting Officer
?
Atkinson Edward Morrow Iii
EVP, Chief Technical Ops. Off.
Vertex Pharmaceuticals Incorporated
US, Boston [HQ]
CIK
1914164
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
30,084
Price per Share :
$419.92
Equivalence :
$12,632,873.28
Transaction History
-
A30,084 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/14/24
-
Footnotes
-
-
Footnotes:#1 Represents earned performance shares with respect to a performance stock unit award granted on 05/19/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 05/14/2024 and the shares will vest on 06/10/2024.
-
F23,260 Shares After TransactionValue : $11,210,389.60$3,288,895.04Transaction Date : 06/11/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024.
-
S15,972 Shares After TransactionValue : $7,634,616.00Sold $3,483,664.00Transaction Date : 06/12/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024.
-
A16,205 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/06/24
-
Footnotes
-
-
Footnotes:#1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.#2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.#3 Restricted stock unit award that vests in installments beginning on 02/17/2025.
-
A20,139 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/06/24
-
Footnotes
-
-
Footnotes:#1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.#2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.#3 Restricted stock unit award that vests in installments beginning on 02/17/2025.